



[www.MedChemExpress.com](http://www.MedChemExpress.com)











Inhibitors, Screening Libraries, Proteins











# GABA Receptor

Gamma-aminobutyric acid Receptor;  $\gamma$ -Aminobutyric acid Receptor

GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known as metabotropic receptors). It has long been recognized that the fast response of neurons to GABA that is blocked by bicuculline and picrotoxin is due to direct activation of an anion channel. This channel was subsequently termed the GABAA receptor. Fast-responding GABA receptors are members of family of Cys-loop ligand-gated ion channels. A slow response to GABA is mediated by GABAB receptors, originally defined on the basis of pharmacological properties.

## GABA Receptor Agonists, Antagonists, Inhibitors, Activators & Modulators











<p><b>(+)-Kavain</b></p> <p>Cat. No.: HY-B1671</p>	<p><b>(-)-Bicuculline methobromide</b> (l-Bicuculline methobromide)</p> <p>Cat. No.: HY-100783</p>
<p>(+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na<sup>+</sup> and Ca<sup>2+</sup> channels.</p>  <p><b>Purity:</b> 99.98% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg</p>	<p>(-)-Bicuculline methobromide (l-Bicuculline methobromide) is a potent GABA<sub>A</sub> receptor antagonist. (-)-Bicuculline methobromide blocks afterhyperpolarizations (AHPs) mediated by Ca<sup>2+</sup>-activated K<sup>+</sup> channels in various types of neurons.</p>  <p><b>Purity:</b> 98.06% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mg</p>
<p><b>(-)-Bicuculline methochloride</b> (l-Bicuculline methochloride)</p> <p>Cat. No.: HY-100783A</p>	<p><b>(-)-Securinine</b></p> <p>Cat. No.: HY-N2079</p>
<p>(-)-Bicuculline methochloride (l-Bicuculline methochloride) is a potent GABA<sub>A</sub> receptor antagonist. (-)-Bicuculline methochloride blocks afterhyperpolarizations (AHPs) mediated by Ca<sup>2+</sup>-activated K<sup>+</sup> channels in various types of neurons.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>(-)-Securinine is plant-derived alkaloid and also a GABA<sub>A</sub> receptor antagonist.</p>  <p><b>Purity:</b> ≥98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 25 mg</p>
<p><b>(-)-α-Pinene</b></p> <p>Cat. No.: HY-N0549</p>	<p><b>(2S)-6-Prenylnarigenin</b></p> <p>Cat. No.: HY-107198</p>
<p>(-)-α-Pinene is a monoterpene and shows sleep enhancing property through a direct binding to GABAA-benzodiazepine (BZD) receptors by acting as a partial modulator at the BZD binding site.</p>  <p><b>Purity:</b> 99.63% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 100 mg, 1 g, 5 g</p>	<p>(2S)-6-Prenylnarigenin is the most efficient compound in forebrain. (2S)-6-Prenylnarigenin acts as a GABA<sub>A</sub> positive allosteric modulator at α+β- binding interface.</p>  <p><b>Purity:</b> 99.78% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>(E)-GABAB receptor antagonist 1</b></p> <p>Cat. No.: HY-129636</p>	<p><b>(R)-Baclofen</b> (Arbaclofen; STX209)</p> <p>Cat. No.: HY-17354</p>
<p>(E)-GABAB receptor antagonist 1 is a trans-GABAB receptor antagonist 1. GABAB receptor antagonist 1 (compound 14) is a selective and negative allosteric modulator of GABAB (γ-Aminobutyric acid) receptors.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>(R)-Baclofen (Arbaclofen) is a selective GABAB receptor agonist.</p>  <p><b>Purity:</b> 99.49% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>
<p><b>(R)-Baclofen hydrochloride</b> (Arbaclofen hydrochloride; STX 209 hydrochloride)</p> <p>Cat. No.: HY-17354A</p>	<p><b>(R)-Baclofen-d4</b> (Arbaclofen-d4; STX209-d4)</p> <p>Cat. No.: HY-17354S</p>
<p>(R)-Baclofen hydrochloride (Arbaclofen hydrochloride) is a selective GABAB receptor agonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p>(R)-Baclofen-d4 (Arbaclofen-d4) is the deuterium labeled (R)-Baclofen. (R)-Baclofen (Arbaclofen) is a selective GABAB receptor agonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>(S)-SNAP5114</b></p> <p>Cat. No.: HY-103504</p> <p>(S)-SNAP5114 is a selective <b>GABA transport</b> inhibitor, with <math>IC_{50}</math> values of 5 <math>\mu</math>M and 21 <math>\mu</math>M for hGAT-3 and rGAT-2, respectively. (S)-SNAP5114 is an anticonvulsant drug.</p>  <p><b>Purity:</b> 98.80%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>	<p><b>12,14-Dichlorodehydroabietic acid</b></p> <p>Cat. No.: HY-133596</p> <p>12,14-Dichlorodehydroabietic acid, a chlorinated resin acid, is a potent <b>Ca<sup>2+</sup>-activated K<sup>+</sup> (BK) channel</b> opener. 12,14-Dichlorodehydroabietic acid blocks <b>GABA</b>-dependent chloride entry in mammalian brain and operates as a non-competitive <b>GABA<sub>A</sub></b> antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>17-PA</b></p> <p>Cat. No.: HY-103495</p> <p>17-PA is a selective antagonist of neurosteroid potentiation and direct gating of <b>GABA<sub>A</sub></b> receptors.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>17<math>\beta</math>-Estradiol sulfate sodium</b> (17<math>\beta</math>-Estradiol 3-sulfate sodium)</p> <p>Cat. No.: HY-141672</p> <p>17<math>\beta</math>-Estradiol sulfate (sodium), also known as <math>\beta</math>-Estradiol 3-sulfate sodium salt, is a neuroactive steroid.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>17<math>\beta</math>-Estradiol sulfate-d4 sodium</b> (17<math>\beta</math>-Estradiol 3-sulfate-d4 sodium)</p> <p>Cat. No.: HY-141672S1</p> <p>17<math>\beta</math>-Estradiol sulfate-d4 (sodium) is the deuterium labeled 17<math>\beta</math>-Estradiol sulfate 17<math>\beta</math>-Estradiol sulfate (sodium), also known as <math>\beta</math>-Estradiol 3-sulfate sodium salt, is a neuroactive steroid.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>17<math>\beta</math>-Estradiol sulfate-d5 sodium</b> (17<math>\beta</math>-Estradiol 3-sulfate-d5 sodium)</p> <p>Cat. No.: HY-141672S</p> <p>17<math>\beta</math>-Estradiol sulfate-d5 (17<math>\beta</math>-Estradiol 3-sulfate-d5) sodium is the deuterium labeled 17<math>\beta</math>-Estradiol sulfate sodium. 17<math>\beta</math>-Estradiol sulfate sodium, also known as <math>\beta</math>-Estradiol 3-sulfate sodium salt, is a neuroactive steroid.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>2'-O-Methylisiquiritigenin</b></p> <p>Cat. No.: HY-N1745</p> <p>2'-O-Methylisiquiritigenin, isolated from the Arachis species, up-regulates 5-HT, NE, DA and <b>GABA</b> pathways, but does not put a very significant effect on ne NE pathway.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>2'MeO6MF</b></p> <p>Cat. No.: HY-131997</p> <p>2'MeO6MF is a brain-penetrant positive allosteric modulator at <math>\alpha 2\beta 1\gamma 2L</math> and all <math>\alpha 1</math>-containing <b>GABA<sub>A</sub></b> receptors. 2'MeO6MF also can directly activate <math>\alpha 2\beta 2/3</math> and <math>\alpha 2\beta 2/3\gamma 2L</math> <b>GABA<sub>A</sub></b> receptors. 2'MeO6MF has anxiolytic and psychomotor stabilizing properties.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>3,4,5-Trimethoxycinnamic acid</b></p> <p>Cat. No.: HY-W012123</p> <p>3,4,5-Trimethoxycinnamic acid is a phenylpropanoid isolated from the roots of Polygala tenuifolia WILLD, with anti-stress effect, prolonging the sleeping time in animals.</p>  <p><b>Purity:</b> 99.22%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p><b>3-Aminopropylphosphinic acid</b> (3-APPA; CGP 27492; CGA 147823)</p> <p>Cat. No.: HY-115763</p> <p>3-Aminopropylphosphinic acid (3-APPA) is a phosphonic analog of <b>GABA</b>. 3-Aminopropylphosphinic acid is a potent, selective <b>GABA<sub>B</sub></b> receptor agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>

<p><b>3-Methyl-GABA</b></p> <p>Cat. No.: HY-115685</p>	<p><b>3<math>\alpha</math>,21-Dihydroxy-5<math>\alpha</math>-pregnan-20-one (THDOC)</b></p> <p>Cat. No.: HY-123489</p>
<p>3-Methyl-GABA is a potent GABA aminotransferase activator. 3-Methyl-GABA can fit the binding pocket of GABA<sub>A</sub> receptor (GABA<sub>A</sub>R). 3-Methyl-GABA can activate L-glutamic acid decarboxylase (GAD). 3-Methyl-GABA has anticonvulsant activity.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>3<math>\alpha</math>,21-Dihydroxy-5<math>\alpha</math>-pregnan-20-one (THDOC), an endogenous neurosteroid, is a positive modulator of GABA<sub>A</sub> receptors. 3<math>\alpha</math>,21-Dihydroxy-5<math>\alpha</math>-pregnan-20-one potentiates neuronal response to low concentrations of GABA at <math>\alpha</math>4<math>\beta</math>1<math>\delta</math> GABA<sub>A</sub> receptors in vitro.</p> <p><b>Purity:</b> <math>\geq</math>97.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg</p>
<p><b>3<math>\alpha</math>,21-Dihydroxy-5<math>\alpha</math>-pregnan-20-one-d3 (THDOC-d3)</b></p> <p>Cat. No.: HY-123489S</p>	<p><b>4-Acetamidobutanoic acid (N-acetyl GABA)</b></p> <p>Cat. No.: HY-101411</p>
<p>3<math>\alpha</math>,21-Dihydroxy-5<math>\alpha</math>-pregnan-20-one-d3 (THDOC-d3) is the deuterium labeled 3<math>\alpha</math>,21-Dihydroxy-5<math>\alpha</math>-pregnan-20-one.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>4-Acetamidobutanoic acid (N-acetyl GABA), the main metabolite of GABA, exhibits antioxidant and antibacterial activities.</p> <p><b>Purity:</b> <math>\geq</math>98.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 200 mg</p>
<p><b>6,2'-Dihydroxyflavone</b></p> <p>Cat. No.: HY-N6628</p>	<p><b>6-Methylflavone</b></p> <p>Cat. No.: HY-N6630</p>
<p>6,2'-Dihydroxyflavone is a novel antagonist of GABA<sub>A</sub> receptor.</p> <p><b>Purity:</b> 99.88%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>	<p>6-Methylflavone is an activator of <math>\alpha</math><sub>1</sub><math>\beta</math><sub>2</sub><math>\gamma</math><sub>2L</sub> and <math>\alpha</math><sub>1</sub><math>\beta</math><sub>2</sub> GABA<sub>A</sub> receptors.</p> <p><b>Purity:</b> 99.49%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>
<p><b>Acamprosate calcium (Calcium N-acetylhomotaurinate)</b></p> <p>Cat. No.: HY-17030</p>	<p><b>Acamprosate D3 calcium</b></p> <p>Cat. No.: HY-17030S</p>
<p>Acamprosate calcium (Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction.</p> <p><b>Purity:</b> <math>\geq</math>98.0%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>	<p>Acamprosate D3 calcium is the deuterium labeled Acamprosate calcium. Acamprosate calcium is a GABA receptor agonist and modulator of glutamatergic systems.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>Acamprosate-d6 calcium</b></p> <p>Cat. No.: HY-110233S</p>	<p><b>Adiplon (NG2-73)</b></p> <p>Cat. No.: HY-14758</p>
<p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 10 mg, 50 mg</p>	<p>Adiplon (NG2-73) is a selective GABA<sub>A</sub> receptor positive allosteric modulator. Adiplon is particularly useful in the treatment of a variety of central nervous system (CNS) disorders.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>

<p><b>ADX71441</b></p> <p>Cat. No.: HY-118301</p>	<p><b>Afizagabar</b> (S44819; Egis-13529)</p> <p>Cat. No.: HY-120051</p>
<p>ADX71441 is a potent and selective positive allosteric modulator of the <math>GABA_B</math> receptor. ADX71441 is bioavailable after oral administration and is brain penetrant. ADX71441 has the potential for research of anxiety, pain and spasticity.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the <math>\alpha 5</math>-<math>GABA_A</math>R, with an <math>IC_{50}</math> of 585 nM for <math>\alpha 5\beta 2\gamma 2</math> and a <math>K_i</math> of 66 nM for <math>\alpha 5\beta 3\gamma 2</math>. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy.</p> <p><b>Purity:</b> 98.23%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Afloqualone</b> (HQ-495)</p> <p>Cat. No.: HY-B1833</p>	<p><b>Afoxolaner</b></p> <p>Cat. No.: HY-16974</p>
<p>Afloqualone (HQ-495) is a GABAergic agent and has agonist activity at the <math>\beta</math> subtype of the <math>GABA_A</math> receptor. Afloqualone has antivertiginous effects thought to be attributable to the increased sensitivity of GABA receptors of the LVN neuron site.</p> <p><b>Purity:</b> <math>\geq</math>98.0%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p>Afoxolaner is an orally active isoxazoline insecticide/acaricide against <i>Ixodes scapularis</i> in dogs.</p> <p><b>Purity:</b> 99.53%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Alogabat</b></p> <p>Cat. No.: HY-132806</p>	<p><b>alpha-Asarone</b> (<math>\alpha</math>-Asarone; trans-Asarone)</p> <p>Cat. No.: HY-N0700</p>
<p>Alogabat (example 8) is a <math>GABA_A \alpha 5</math> receptor positive allosteric modulators (PAMs) (extracted from patent WO2018104419A1).</p> <p><b>Purity:</b> 99.91%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg</p>	<p>alpha-Asarone (<math>\alpha</math>-Asarone) is one of the main psychoactive compounds, and possesses an antidepressant-like activity in mice.</p> <p><b>Purity:</b> 99.57%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>
<p><b>Alpidem</b> (Ananxyl)</p> <p>Cat. No.: HY-W013150</p>	<p><b>Aminoxyacetic acid hemihydrochloride</b> (Carboxymethoxyamine hemihydrochloride; Aminoxyacetate hemihydrochloride)</p> <p>Cat. No.: HY-107994</p>
<p>Alpidem selectively binds to <math>\alpha 1\beta 2\gamma 2</math> subunit-containing <math>GABA_A</math> receptor with an <math>IC_{50}</math> of 17 nM and exerts anxiolytic effect.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Aminoxyacetic acid (Carboxymethoxyamine) hemihydrochloride is a malate-aspartate shuttle (MAS) inhibitor which also inhibits the GABA degrading enzyme <math>GABA-T</math>.</p> <p><b>Purity:</b> <math>\geq</math>98.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>
<p><b>Anisatin</b></p> <p>Cat. No.: HY-N9506</p>	<p><b>Arbaclofen placarbil</b> (XP 19986)</p> <p>Cat. No.: HY-14735</p>
<p>Anisatin, a pure toxic substance isolated from the seeds of a Japanese plant (<i>Illicium anisatum</i>) acts as a picrotoxin-like, non-competitive <math>GABA</math> antagonist.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p>Arbaclofen placarbil is a novel transported prodrug of the active R-isomer of baclofen. Baclofen is a racemic <math>GABA_B</math> receptor agonist.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>

<p><b>Arecaidine</b></p> <p>Cat. No.: HY-N2368</p>	<p><b>Arecaidine hydrochloride</b></p> <p>Cat. No.: HY-N2368A</p>
<p>Arecaidine, a pyridine alkaloid, is a potent <b>GABA uptake</b> inhibitor. Arecaidine is a substrate of H<sup>+</sup>-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits <b>L-proline uptake</b>.</p> <p><b>Purity:</b> 99.58%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg</p>	<p>Arecaidine hydrochloride, a pyridine alkaloid, is a potent <b>GABA uptake</b> inhibitor. Arecaidine hydrochloride is a substrate of H<sup>+</sup>-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits <b>L-proline uptake</b>.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>AZD-6280</b></p> <p>Cat. No.: HY-19872</p>	<p><b>AZD7325</b></p> <p>Cat. No.: HY-111052</p>
<p>AZD-6280 is a selective <b>GABAA(α2/3) receptor</b> modulator, used for treatment of generalized anxiety disorder.</p> <p><b>Purity:</b> 99.22%</p> <p><b>Clinical Data:</b> Phase 1</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg, 20 mg</p>	<p>AZD7325 is a potent and orally active partial selective PAM of <b>GABAAα2 and α3 receptor</b> (K<sub>i</sub>=0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the α1 and α5 receptor subtypes.</p> <p><b>Purity:</b> 98.88%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>Baclofen</b></p> <p>Cat. No.: HY-B0007</p>	<p><b>Baclofen-d4</b></p> <p>Cat. No.: HY-B0007S</p>
<p>Baclofen, a lipophilic derivative of γ-aminobutyric acid (GABA), is an orally active, selective metabotropic <b>GABA-B receptor (GABA<sub>B</sub>R)</b> agonist. Baclofen has high blood brain barrier penetration. Baclofen has the potential for muscle spasticity research.</p> <p><b>Purity:</b> 99.42%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 500 mg, 1 g, 5 g</p>	<p>Baclofen-d4 is the deuterium labeled Baclofen. Baclofen, a lipophilic derivative of γ-aminobutyric acid (GABA), is an orally active, selective metabotropic <b>GABA-B receptor (GABA<sub>B</sub>R)</b> agonist. Baclofen has high blood brain barrier penetration.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 10 mg</p>
<p><b>Bamaluzole</b></p> <p>Cat. No.: HY-100124</p>	<p><b>Basmisanil</b></p> <p>(RG1662; RO5186582)</p> <p>Cat. No.: HY-16716</p>
<p>Bamaluzole is a <b>GABA receptor</b> agonist extracted from patent WO 2012064642 A1.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Basmisanil is a highly selective <b>GABAAα5</b> negative allosteric modulator.</p> <p><b>Purity:</b> 99.89%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>Bemegride</b></p> <p>(3-Ethyl-3-methylglutarimide; Bemegrid)</p> <p>Cat. No.: HY-B1326</p>	<p><b>Bicuculline</b></p> <p>(+)-Bicuculline; d-Bicuculline)</p> <p>Cat. No.: HY-N0219</p>
<p>Bemegride (3-Ethyl-3-methylglutarimide) is a central nervous system stimulant and antidote for barbiturate poisoning.</p> <p><b>Purity:</b> 99.92%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>Bicuculline ((+)-Bicuculline; d-Bicuculline), as a convulsant alkaloid, is a competitive neurotransmitter <b>GABA<sub>A</sub></b> receptor antagonist (IC<sub>50</sub>=2 μM). Bicuculline also blocks Ca<sup>2+</sup>-activated potassium (SK) channels and subsequently blocks the slow afterhyperpolarization (slow AHP) .</p> <p><b>Purity:</b> 99.97%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg</p>

<p><b>Bifenazate</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-119687</p> <p>Bifenazate is a carbamate acaricide that control 100% of mites at a concentration of 25 ppm. Bifenazate is a positive allosteric modulator of <b>GABA<sub>A</sub> receptor</b>.</p>  <p><b>Purity:</b> 99.65%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg, 1 g</p>	<p><b>Bis(7)-tacrine dihydrochloride</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-120970</p> <p>Bis(7)-tacrine dihydrochloride is a dimeric <b>AChE</b> inhibitor derived from tacrine. Bis(7)-tacrine dihydrochloride prevents glutamate-induced neuronal apoptosis by blocking NMDA receptors. Bis(7)-tacrine dihydrochloride is a potent <b>GABA<sub>A</sub> receptor</b> antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Broflanilide</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-108689</p> <p>Broflanilide is a potential insecticide and metabolized to Desmethyl-Broflanilide, which is a potent antagonist at the insect resistant-to-dieldrin (RDL) <b>GABA Receptor</b>, and inhibits <i>S. litura</i> RDL GABAR, with an <b>IC<sub>50</sub></b> value of 1.3 nM.</p>  <p><b>Purity:</b> 99.10%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Carburazepam</b> (RGH 3331; Uxepam)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-U00241</p> <p>Carburazepam is a drug which derives from benzodiazepine. Benzodiazepines (BZD, BZs) are a class of psychoactive drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg</p>
<p><b>CGP 36742</b> (SGS-742)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-121599</p> <p>CGP 36742 is a selective <b>GABA<sub>B</sub> receptor</b> antagonist that can penetrate the blood–brain barrier after peripheral administration, with an <b>IC<sub>50</sub></b> of 32μM. CGP 36742 is useful in treatment of depression.</p>  <p><b>Purity:</b> ≥97.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg</p>	<p><b>CGP 54626 hydrochloride</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-101378</p> <p>CGP 54626 (hydrochloride) is a selective antagonist of <b>GABA<sub>B</sub> receptor</b> with an <b>IC<sub>50</sub></b> value of 4 nM. CGP 54626 (hydrochloride) can be used to investigate the role of <b>GABA<sub>B</sub> receptors</b> in neurological signaling.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>CGP11952</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-U00192</p> <p>CGP11952 is a triazolyl-Benzapenon resembling the benzodiazepines in its pharmacological action. CGP11952 is an experimental <b>benzodiazepine</b> derivative.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>CGP35348</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-103530</p> <p>CGP 35348 is a selective, brain penetrant, centrally active <b>GABAB receptor</b> antagonist with an <b>EC<sub>50</sub></b> of 34 μM. CGP 35348 shows affinity for the GABAB receptor only.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>CGP52432</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-103531</p> <p>CGP52432 is a <b>GABA<sub>B</sub> receptor</b> antagonist, with an <b>IC<sub>50</sub></b> of 85 nM.</p>  <p><b>Purity:</b> 98.17%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>CGP55845 hydrochloride</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-103516</p> <p>CGP55845 hydrochloride is a potent and selective <b>GABAB receptor</b> antagonist with an <b>IC<sub>50</sub></b> of 6 nM. CGP55845 hydrochloride can be used for neurological research.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>

<p><b>CGP7930</b></p> <p>Cat. No.: HY-103502</p>	<p><b>Chlormezanone</b></p> <p>Cat. No.: HY-B0353</p>
<p>CGP7930 (3-(3',5'-Di-tert-butyl-4'-hydroxy)phenyl-2, 2-dimethylpropanol) is a positive <b>metabotropic GABAB receptor</b> allosteric modulator. CGP7930 enhances the inhibitory effect of l-baclofen on the oscillatory activity of cultured cortical neurons.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Chlormezanone resembles <b>benzodiazepine</b>. The action of Chlormezanone is similar to benzodiazepine-type agents. Chlormezanone is used as an anxiolytic and a muscle relaxant.</p> <p><b>Purity:</b> 99.71%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>Cholesterol myristate</b> (Cholesteryl myristate; Cholesteryl tetradecanoate)</p> <p>Cat. No.: HY-N2338</p>	<p><b>Chrodriamin B</b></p> <p>Cat. No.: HY-N8472</p>
<p>Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the <b>nicotinic acetylcholine receptor</b>, <b>GABAA receptor</b>, and the inward-rectifier <b>potassium ion channel</b>.</p> <p><b>Purity:</b> ≥98.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 250 mg</p>	<p>Chrodriamin B, a metabolite of a fungal, is a potent, non-open-channel-blocking antagonist on B. mori <b>GABAR RDL</b> with an <math>IC_{50}</math> of 1.13 nM.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Cipepofol</b> (HSK3486)</p> <p>Cat. No.: HY-116152</p>	<p><b>Cirsimaritin</b></p> <p>Cat. No.: HY-N6648</p>
<p>Cipepofol (HSK3486), a psychomotor stabilizing agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Cirsimaritin binds weakly to the benzodiazepine site on <b>GABA<sub>A</sub></b> receptors, with antidepressant, anxiolytic and antinociceptive activities.</p> <p><b>Purity:</b> 98.18%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>CL 218872</b></p> <p>Cat. No.: HY-103505</p>	<p><b>Clomethiazole</b></p> <p>Cat. No.: HY-129105</p>
<p>CL 218872 is a selective and orally active benzodiazepine of <math>\alpha 1</math> subunit-containing <b>GABA<sub>A</sub> receptor</b> with a <math>K_i</math> of 130 nM. CL 218872 exerts anxiolytic and anticonvulsant in vivo.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Chlormethiazole is a potent and orally active <b>GABA<sub>A</sub></b> agonist. Chlormethiazole inhibits cytochrome P450 isoforms: <b>CYP2A6</b> and <b>CYP2E1</b> in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus.</p> <p><b>Purity:</b> 98.19%</p> <p><b>Clinical Data:</b> Phase 3</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg</p>
<p><b>COR659</b></p> <p>Cat. No.: HY-137204</p>	<p><b>CP-409092</b></p> <p>Cat. No.: HY-101639</p>
<p>COR659 is a potent and effective <b>GABA<sub>B</sub> positive allosteric modulator (PAM)</b>. COR659 suppresses alcohol and chocolate self-administration in rats.</p> <p><b>Purity:</b> 99.94%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>CP-409092 is a partial agonist of <b>GABA<sub>A</sub> receptor</b>, with anti-anxiety activity.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>




<p><b>CP-409092 hydrochloride</b></p> <p>Cat. No.: HY-101639A</p>	<p><b>DAA-1106</b></p> <p>Cat. No.: HY-19945</p>
<p>CP-409092 hydrochloride is a partial agonist of <b>GABA<sub>A</sub> receptor</b>, with anti-anxiety activity.</p> <p><b>Purity:</b> 99.72%</p> <p><b>Clinical Data:</b></p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.</p> <p><b>Purity:</b> 99.71%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Dihydroergotoxine mesylate</b> (Ergoloid mesylates)</p> <p>Cat. No.: HY-B0799</p>	<p><b>DL-Menthol</b> (Racemethol)</p> <p>Cat. No.: HY-Y1683</p>
<p>Dihydroergotoxine mesylate is a complex of closely related alkaloid salts; Binds with high affinity to the GABA<sub>A</sub> receptor Cl<sup>-</sup> channel, producing an allosteric interaction with the benzodiazepine site.</p> <p><b>Purity:</b> ≥98.0%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg</p>	<p>DL-Menthol is a relative configuration of (-)-Menthol. DL-Menthol relates to the activation of GABA<sub>A</sub> receptor.</p> <p><b>Purity:</b> ≥98.0%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM × 1 mL, 500 mg</p> <p>Relative stereochemistry</p>
<p><b>DMCM hydrochloride</b></p> <p>Cat. No.: HY-100369A</p>	<p><b>DS2</b></p> <p>Cat. No.: HY-103520</p>
<p>DMCM hydrochloride is a nonselective full inverse agonist of <b>benzodiazepine</b>. DMCM shows binding affinity at human recombinant <b>GABA<sub>A</sub> αβ3γ2 receptor</b> subtypes with K<sub>s</sub> of 10 nM, 13 nM, 7.5 nM, 2.2 nM for α1, α2, α3, and α5 receptors, respectively.</p> <p><b>Purity:</b> 98.31%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>DS2 is a selective positive allosteric modulator of <b>δ-GABA<sub>A</sub> receptor</b>. DS2 selectively potentiates GABA responses mediated by α4β3δ receptor. DS2 does not enhance activity at α4β3γ2 and α1β3γ2 receptors. DS2 relieves pain and.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Emamectin Benzoate</b> (MK-244)</p> <p>Cat. No.: HY-B0837</p>	<p><b>epi-Aszonalenin A</b></p> <p>Cat. No.: HY-135154</p>
<p>Emamectin Benzoate (MK-244) is an orally active nervous system toxicant by binding γ-aminobutyric (GABA) receptor in insects. Emamectin Benzoate is one of semi-synthetic derivative of Avermectin (HY-15311) with a broad spectrum of <b>insecticidal</b> and acaricidal activity.</p> <p><b>Purity:</b> 99.40%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>epi-Aszonalenin A is a benzodiazepine fungal metabolite originally isolated from <i>Aspergillus novofumigatus</i>. epi-Aszonalenin A can be used as a psychoactive agent.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Ethyl dirazepate</b></p> <p>Cat. No.: HY-101596</p>	<p><b>Etifoxine</b> (HOE 36-801)</p> <p>Cat. No.: HY-16579A</p>
<p>Ethyl dirazepate is a drug which is a <b>benzodiazepine</b> derivative. It has anxiolytic and possibly other characteristic benzodiazepine properties.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing <b>GABA<sub>A</sub> receptors</b>. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents.</p> <p><b>Purity:</b> 99.87%</p> <p><b>Clinical Data:</b> Phase 3</p> <p><b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

### Etifoxine hydrochloride

(HOE 36-801 hydrochloride)

Cat. No.: HY-16579

Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of  $\alpha 1\beta 2\gamma 2$  and  $\alpha 1\beta 3\gamma 2$  subunit-containing **GABA<sub>A</sub> receptors**. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents.




**Purity:** 99.87%  
**Clinical Data:** Phase 3  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Etifoxine-d3

Cat. No.: HY-16579AS

Etifoxine-d3 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of  $\alpha 1\beta 2\gamma 2$  and  $\alpha 1\beta 3\gamma 2$  subunit-containing **GABA<sub>A</sub> receptors**. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg

### Etifoxine-d5

Cat. No.: HY-16579AS2

Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of  $\alpha 1\beta 2\gamma 2$  and  $\alpha 1\beta 3\gamma 2$  subunit-containing **GABA<sub>A</sub> receptors**. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Etiocholanolone

(5 $\beta$ -Androsterone)

Cat. No.: HY-113320

Etiocholanolone (5 $\beta$ -Androsterone) is the excreted **metabolite** of testosterone and has anticonvulsant activity. Etiocholanolone is a less potent neurosteroid positive allosteric modulator (PAM) of the **GABA<sub>A</sub> receptor** than its enantiomer form.




**Purity:** ≥98.0%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg

### Etiocholanolone-d2

(5 $\beta$ -Androsterone-d2)

Cat. No.: HY-113320S1

Etiocholanolone-d2 is the deuterium labeled Etiocholanolone. Etiocholanolone (5 $\beta$ -Androsterone) is the excreted **metabolite** of testosterone and has anticonvulsant activity.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Etiocholanolone-d5

Cat. No.: HY-113320S

Etiocholanolone-d5 is the deuterium labeled Etiocholanolone. Etiocholanolone (5 $\beta$ -Androsterone) is the excreted **metabolite** of testosterone and has anticonvulsant activity.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Etomidate

(R 16659)

Cat. No.: HY-B0100

Etomidate (R 16659) is a potent **GABA<sub>A</sub> receptor** agonist. Etomidate is a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia.




**Purity:** 99.68%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

### Etomidate hydrochloride

(R16659 hydrochloride)

Cat. No.: HY-B0100A

Etomidate hydrochloride (R 16659 hydrochloride) is a potent **GABA<sub>A</sub> receptor** agonist. Etomidate hydrochloride is a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia.




**Purity:** 99.50%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

### Etomidate-d5

(R 16659-d5)

Cat. No.: HY-B0100S

Etomidate-d5 is deuterium labeled Etomidate. Etomidate (R 16659) is a potent **GABA<sub>A</sub> receptor** agonist. Etomidate is a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Fengabine

(SL 79229)











Cat. No.: HY-123478











Fengabine is a GABAergic antidepressant drug. Fengabine can be used for the research of depression.























**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg











<p><b>FG 7142</b> (ZK 39106; LSU-65)</p>	<p><b>FG8119</b> (NNC13-8119)</p>
<p>FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the <math>\alpha 1</math> subunit-containing <b>GABAA receptor</b> (<math>K_i=91</math> nM).</p> <p><b>Purity:</b> 98.06% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 2 mg, 5 mg, 10 mg</p>	<p>FG8119 is a novel <b>benzodiazepine agonist</b> extracted from patent US 4745112 A.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Fipronil</b></p>	<p><b>Flufiprole</b></p>
<p>Fipronil is an insecticide that acts as a selective antagonist of <b>insect GABA receptors</b> (<math>IC_{50}</math>s = 30 nM and 1,600 nM for <b>cockroach</b> and <b>rat receptors</b>, respectively).</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg</p>	<p>Flufiprole is a nonsystemic phenylpyrazole insecticide targeting the <b>GABA receptor</b> used in the rice field. Flufiprole is excellent in controlling a wide range of pests.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Flumazenil</b> (Ro 15-1788)</p>	<p><b>Flumazenil acid</b> (Ro 15-3890)</p>
<p>Flumazenil is a competitive <b>GABAA receptor</b> antagonist, used in the treatment of benzodiazepine overdoses.</p> <p><b>Purity:</b> 99.97% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>	<p>Flumazenil acid is a metabolite of Flumazenil. Flumazenil is a <b>GABAA receptor</b> antagonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>
<p><b>Fluxametamide</b></p>	<p><b>Furosemide</b></p>
<p>Fluxametamide is an insecticide with wide spectrum, acts as an antagonist of <b>GABA- and glutamate-gated chloride channels</b>, with <math>IC_{50}</math> of 1.95 nM and 225 nM for <i>M. domestica</i> GABACls and GluCls.</p> <p><b>Purity:</b> 98.66% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg</p>	<p>Furosemide is a potent and orally active inhibitor of <b>Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> (NKCC) cotransporter</b>, NKCC1 and NKCC2.</p> <p><b>Purity:</b> 99.52% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g, 5 g</p>
<p><b>Furosemide sodium</b></p>	<p><b>Furosemide-d5</b></p>
<p>Furosemide sodium is a potent and orally active inhibitor of <b>Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> (NKCC) cotransporter</b>, NKCC1 and NKCC2.</p> <p><b>Purity:</b> 99.72% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g</p>	<p>Furosemide-d5 is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of <b>Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> (NKCC) cotransporter</b>, NKCC1 and NKCC2.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 10 mg</p>

<p><b>GABAA receptor agent 1</b></p> <p>Cat. No.: HY-133486</p>	<p><b>GABAA receptor agent 2 TFA</b></p> <p>Cat. No.: HY-135482</p>
<p>GABAA receptor agent 1 is a high affinity ligand for <b>GABAA receptor</b>, with potent anticonvulsant activity.</p>  <p><b>Purity:</b> 98.93%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>GABAA receptor agent 2 TFA is a potent and high-affinity <b>GABA<sub>A</sub> receptor</b> antagonist with an <b>IC<sub>50</sub></b> of 24 nM (human <math>\alpha 1\beta 2\gamma 2</math> GABA<sub>A</sub>-expressing tsA201 cells) and a <b>K<sub>i</sub></b> of 28 nM (<b>rat GABA<sub>A</sub> receptors</b>).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>GABAA receptor agent 4</b></p> <p>Cat. No.: HY-145256</p>	<p><b>GABAA receptor agent 5</b></p> <p>Cat. No.: HY-145257</p>
<p>GABAA receptor agent 4 (compound 1e) is a potent <math>\gamma</math>-<b>GABAAR</b> antagonist with an <b>K<sub>i</sub></b> of 0.18 <math>\mu</math>M. GABAA receptor agent 4 efficiently rescues inhibition of T cell proliferation. GABAA receptor agent 4 has the immunomodulatory potential.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>GABAA receptor agent 5 (compound 018) is a potent <math>\gamma</math>-<b>GABAAR</b> antagonist with an <b>K<sub>i</sub></b> of 0.020 <math>\mu</math>M. GABAA receptor agent 5 shows <math>\gamma</math>-<b>GABAAR</b> antagonist activity with low cellular membrane permeability.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>GABAA receptor agent 6</b></p> <p>Cat. No.: HY-145258</p>	<p><b>GABAB receptor antagonist 1</b></p> <p>Cat. No.: HY-129636A</p>
<p>GABAA receptor agent 6 (compound 2027) is a potent <math>\gamma</math>-<b>GABAAR</b> antagonist with an <b>K<sub>i</sub></b> of 0.56 <math>\mu</math>M. GABAA receptor agent 6 shows <math>\gamma</math>-<b>GABAAR</b> antagonist activity with low cellular membrane permeability.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p>GABAB receptor antagonist 1 (compound 14) is a selective and negative allosteric modulator of <b>GABAB (<math>\gamma</math>-Aminobutyric acid) receptors</b>. (E)-GABAB receptor antagonist 1 decreases GABA-induced IP3 (inositol trisphosphate) production with <b>IC<sub>50</sub></b> of 37.9 <math>\mu</math>M.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Gabazine</b> (SR95531)</p> <p>Cat. No.: HY-103533</p>	<p><b>Gaboxadol hydrochloride</b> (Lu 02-030 hydrochloride; THIP hydrochloride)</p> <p>Cat. No.: HY-10233</p>
<p>Gabazine is a selective and competitive antagonist of <b>GABA<sub>A</sub> receptor</b>, with an <b>IC<sub>50</sub></b> of ~0.2 <math>\mu</math>M for GABA receptor.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Gaboxadol hydrochloride (Lu 02-030 hydrochloride) is a potent agonist of the <b>GABA<sub>A</sub> receptor</b> and an antagonist of <b>GABA<sub>C</sub> receptors</b> (<b>IC<sub>50</sub></b>=25 <math>\mu</math>M).</p>  <p><b>Purity:</b> 99.34%  <b>Clinical Data:</b> Phase 3  <b>Size:</b> 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Ginkgolide A</b> (BN-52020)</p> <p>Cat. No.: HY-B0355</p>	<p><b>Ginsenoside Rc</b> (Panaxoside Rc)</p> <p>Cat. No.: HY-N0042</p>
<p>Ginkgolide A (BN-52020) is an extract from in Ginkgo biloba and a <math>\gamma</math>-aminobutyric acid (GABA) antagonist.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg</p>	<p>Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptor (<b>GABA<sub>A</sub></b>)-mediated ion channel currents (<b>I<sub>GABA<sub>A</sub></sub></b>). Ginsenoside Rc inhibits the expression of <b>TNF-<math>\alpha</math></b> and <b>IL-1<math>\beta</math></b>.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg</p>











<p><b>Guvacine</b></p> <p>Cat. No.: HY-N2482</p> <p>Guvacine, an alkaloid found in the nut of <i>Areca catechu</i>, is a potent <b>GABA uptake</b> inhibitor. Guvacine inhibits <b>rat GAT-1</b>, <b>rat GAT-2</b> and <b>rat GAT-3</b> with <b>IC<sub>50</sub></b> values of 39 <math>\mu</math>M, 58 <math>\mu</math>M and 378 <math>\mu</math>M, respectively.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg</p> 	<p><b>Guvacine hydrochloride</b></p> <p>Cat. No.: HY-100809</p> <p>Guvacine hydrochloride is an alkaloid from the nut of <i>Areca catechu</i>, acts as an inhibitor of <b>GABA transporter</b>, and displays modest selectivity for cloned GABA transporters with <b>IC<sub>50</sub>s</b> of 14 <math>\mu</math>M (human GAT-1), 39 <math>\mu</math>M (rat GAT-1), 58 <math>\mu</math>M (rat GAT-2), 119 <math>\mu</math>M (human GAT-3), 378 <math>\mu</math>M (rat...)</p> <p><b>Purity:</b> 99.73%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p> 
<p><b>Homocarnosine</b> (L-Homocarnosine; <math>\gamma</math>-Aminobutyryl-L-histidine)</p> <p>Cat. No.: HY-114883</p> <p>Homocarnosine is a dipeptide of <math>\gamma</math>-aminobutyric acid (<b>GABA</b>) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Homocarnosine TFA</b> (L-Homocarnosine TFA; <math>\gamma</math>-Aminobutyryl-L-histidine TFA)</p> <p>Cat. No.: HY-114883A</p> <p>Homocarnosine TFA is a dipeptide of <math>\gamma</math>-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects.</p> <p><b>Purity:</b> 98.26%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p><b>Humulone</b> (<math>\alpha</math>-Lupulic acid)</p> <p>Cat. No.: HY-N6084</p> <p>Humulone (<math>\alpha</math>-Lupulic acid), a prenylated phloroglucinol derivative, is a potent <b>cyclooxygenase-2 (COX-2)</b> inhibitor. Humulone acts as a positive modulator of <b>GABA<sub>A</sub> receptor</b> at low micromolar concentrations. Humulone is an inhibitor of bone resorption.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg</p> 	<p><b>Imepitoin</b> (AWD 131-138)</p> <p>Cat. No.: HY-14953</p> <p>Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.</p> <p><b>Purity:</b> 99.43%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p><b>Isoguvacine hydrochloride</b></p> <p>Cat. No.: HY-100810</p> <p>Isoguvacine hydrochloride is a <b>GABA receptor</b> agonist.</p> <p><b>Purity:</b> 98.80%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 25 mg, 50 mg, 100 mg</p> 	<p><b>Jujuboside A</b></p> <p>Cat. No.: HY-N0659</p> <p>Jujuboside A is a glycoside extracted from <i>Semen Ziziphi Spinosae</i>, a Chinese herbal medicine used to treat insomnia and anxiety.</p> <p><b>Purity:</b> 99.88%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p><b>Kavain</b></p> <p>Cat. No.: HY-N2096</p> <p>Kavain is a class of kavalactone isolated from <i>Piper methysticum</i>, which has anxiolytic properties in animals and humans. Kavain positively modulated <b><math>\gamma</math>-Aminobutyric acid type A (GABA<sub>A</sub>) receptor</b>.</p> <p><b>Purity:</b> 99.77%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg, 500 mg</p> 	<p><b>L-655708</b></p> <p>Cat. No.: HY-14426</p> <p>L-655708 is a potent <math>\alpha 5</math> subunit-selective <b>GABA<sub>A</sub> receptor</b> inverse agonist (<b>K<sub>i</sub></b>=0.45 nM).</p> <p><b>Purity:</b> 99.25%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg</p> 

<p><b>L-838417</b></p> <p>Cat. No.: HY-W009009</p> <p>L-838417 is a selective partial agonist at the <math>\alpha 2</math>, <math>\alpha 3</math> and <math>\alpha 5</math> subtypes of the GABA<sub>A</sub> receptor and an antagonist at the <math>\alpha 1</math>, with binding <math>K_i</math> values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for <math>\alpha 1\beta 3\gamma 2</math>, <math>\alpha 2\beta 3\gamma 2</math>, <math>\alpha 3\beta 3\gamma 2</math>, <math>\alpha 4\beta 3\gamma 2</math>, <math>\alpha 5\beta 3\gamma 2</math> and <math>\alpha 6\beta 3\gamma 2</math>.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>		<p><b>L-Cycloserine</b> (S)-Cycloserine; (S)-4-Amino-3-isoxazolidone</p> <p>Cat. No.: HY-B1122</p> <p>L-Cycloserine ((S)-4-Amino-3-isoxazolidone) irreversibly inhibits GABA pyridoxal 5'-phosphate-dependent aminitransferase in E.</p> <p><b>Purity:</b> 99.13%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mg, 50 mg, 100 mg</p>	
<p><b>L-DABA</b> (L-2,4-Diaminobutyric acid)</p> <p>Cat. No.: HY-101414</p> <p>L-DABA (L-2,4-Diaminobutyric acid) is a weak GABA transaminase inhibitor with an <math>IC_{50}</math> of larger than 500 <math>\mu</math>M; exhibits antitumor activity in vivo and in vitro.</p> <p><b>Purity:</b> <math>\geq 98.0\%</math></p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 100 mg</p>		<p><b>LAU159</b></p> <p>Cat. No.: HY-112426</p> <p>LAU159 is a functionally selective positive modulator of <math>\alpha 1\beta 3</math> GABA(A) receptor with an <math>EC_{50}</math> of 2.2 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	
<p><b>Lesogaberan</b> (AZD-3355)</p> <p>Cat. No.: HY-10061</p> <p>Lesogaberan (AZD-3355) is a potent and selective GABA<sub>B</sub> receptor agonist with an <math>EC_{50}</math> of 8.6 nM for human recombinant GABA<sub>B</sub> receptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg</p>		<p><b>Lesogaberan hydrochloride</b> (AZD-3355 hydrochloride)</p> <p>Cat. No.: HY-10061B</p> <p>Lesogaberan (AZD-3355) hydrochloride is a potent and selective GABA<sub>B</sub> receptor agonist with an <math>EC_{50}</math> of 8.6 nM for human recombinant GABA<sub>B</sub> receptor.</p> <p><b>Purity:</b> <math>\geq 98.0\%</math></p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg</p>	
<p><b>Lesogaberan napadisylate</b> (AZD-3355 napadisylate)</p> <p>Cat. No.: HY-10061A</p> <p>Lesogaberan (AZD-3355) napadisylate is a potent and selective GABA<sub>B</sub> receptor agonist with an <math>EC_{50}</math> of 8.6 nM for human recombinant GABA<sub>B</sub> receptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 1 mg, 5 mg</p>		<p><b>Loreclezole</b> (R 72063)</p> <p>Cat. No.: HY-105272</p> <p>Loreclezole, an antiepileptic compound, is a selective GABA<sub>A</sub> receptor modulator and acts as a positive allosteric modulator of <math>\beta 2</math> or <math>\beta 3</math>-subunit containing receptors.</p> <p><b>Purity:</b> 99.81%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	
<p><b>Loreclezole hydrochloride</b> (R 72063 hydrochloride)</p> <p>Cat. No.: HY-105272A</p> <p>Loreclezole hydrochloride, an antiepileptic compound, is a selective GABA<sub>A</sub> receptor modulator and acts as a positive allosteric modulator of <math>\beta 2</math> or <math>\beta 3</math>-subunit containing receptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>		<p><b>Lorediplon</b></p> <p>Cat. No.: HY-19371</p> <p>Lorediplon is a novel non-benzodiazepine drug acting as a GABA<sub>A</sub> receptor modulator, differentially active at the <math>\alpha 1</math>-subunit, associated with promoting sleep.</p> <p><b>Purity:</b> 99.89%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	

<p><b>Lotilaner</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-116564</p> <p>Lotilaner is a <b>parasiticide</b>, acts as a potent non-competitive antagonist of insects <b>GABAC1 receptors</b>, with an <math>IC_{50}</math> of 23.84 nM for <i>Drosophila melanogaster</i> GABA receptor. No effect on a dog GABAA receptor.</p>  <p><b>Purity:</b> 99.60%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>LU-32-176B</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-118207</p> <p>LU-32-176B, a GABA transporter 1(<b>GAT1</b>) selective inhibitor, is found to exert a synergistic anticonvulsant action with GAT2 transport inhibitor EF1502. LU-32-176B inhibits <b>neurons, astrocytes and mGAT1</b> with the <math>IC_{50}</math> values of 2μM, 1μM, 4μM, respectively.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Methionine</b> (MRX-1024; D-Methionine)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13694</p> <p>Methionine (MRX-1024; D-Methionine) is an effective chemoprotective agent which can also inhibit the neuronal activity through <b>GABA<sub>A</sub></b> receptor activation.</p>  <p><b>Purity:</b> ≥97.0%  <b>Clinical Data:</b> Phase 3  <b>Size:</b> 10 mM × 1 mL, 500 mg, 1 g</p>	<p><b>Methionine-d3</b> (MRX-1024-d3; D-Methionine-d3)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13694S</p> <p>Methionine-d3 is the deuterium labeled Methionine. Methionine (MRX-1024; D-Methionine) is an effective chemoprotective agent which can also inhibit the neuronal activity through GABAA receptor activation.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Methionine-d4</b> (MRX-1024-d4; D-Methionine-d4)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-13694S1</p> <p>Methionine-d4 is the deuterium labeled Methionine. Methionine (MRX-1024; D-Methionine) is an effective chemoprotective agent which can also inhibit the neuronal activity through GABAA receptor activation.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Miltirone</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-N1951</p> <p>Miltirone is a natural compound present in the root of <i>Salvia miltiorrhiza</i>. Miltirone is a central <b>benzodiazepine receptor</b> partial agonist, with an <math>IC_{50}</math> of 0.3 μM.</p>  <p><b>Purity:</b> 99.74%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>
<p><b>MK-0343</b> (MRK-409)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-101869</p> <p>MK0343 (MRK-409) is an orally bioavailable <b>GABA<sub>A</sub></b> receptor subtype-selective partial agonist. MK0343 is a non-sedating anxiolytic.</p>  <p><b>Purity:</b> 99.31%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 1 mg, 5 mg</p>	<p><b>MRK-016</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-100370</p> <p>MRK-016 is a selective, orally bioavailable inverse agonist of <b>GABA<sub>A</sub> α5</b> receptor, with an <math>EC_{50}</math> of 3 nM for GABA<sub>A</sub> α5, and <math>K_i</math>s of 0.83, 0.85, 0.77 and 1.4nM for human GABA<sub>A</sub> α1β3γ2, GABA<sub>A</sub> α2β3γ2, GABA<sub>A</sub> α3β3γ2, and GABA<sub>A</sub> α5β3γ2, respectively; MRK-016 also readily penetrates...</p>  <p><b>Purity:</b> 99.27%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>
<p><b>Nefiracetam</b> (DM9384; DZL-221)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-B0340</p> <p>Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal systems enhancer for Ro 5-4864-induced convulsions.</p>  <p><b>Purity:</b> 99.39%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg</p>	<p><b>NEO 376</b> (SPI-376)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-101583</p> <p>NEO 376 is a selective modulator of <b>5-HT1 receptor, GABA receptor and dopamine receptor</b>, with anti-psychotic actively.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg</p>

<p><b>Nipecotnic acid</b> ((±)-β-Homoproline; Hexahyronicotinic acid; 3-Carboxypiperidine) <span style="float: right;">Cat. No.: HY-69359</span></p> <p>Nipecotnic acid ((±)-β-Homoproline) is a potent inhibitor of neuronal and glial-aminobutyric acid (GABA) uptake in vitro. Nipecotnic acid can also directly activate GABA<sub>A</sub>-like chloride channels, with an EC<sub>50</sub> of approximately 300μM.</p> <p><b>Purity:</b> ≥95.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>NNC-711 hydrochloride</b> (NO-711 hydrochloride) <span style="float: right;">Cat. No.: HY-103506</span></p> <p>NNC-711 (hydrochloride) is a potent and selective inhibitor of GAT-1 (GABA transporter 1) with an IC<sub>50</sub> of 40 nM for hGAT-1. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>NS11394</b> <span style="float: right;">Cat. No.: HY-11048</span></p> <p>NS11394 is an orally active and unique subtype-selective GABA<sub>A</sub> positive allosteric receptor (PAM), with a K<sub>i</sub> of ~0.5 nM. NS11394 shows a selectivity profile in the order of GABA<sub>A</sub>-5 &gt; α3 &gt; α2 &gt; α1-containing receptors.</p> <p><b>Purity:</b> 99.73%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>Ocinaplon</b> (DOV 273547) <span style="float: right;">Cat. No.: HY-W001692</span></p> <p>Ocinaplon (DOV 273547) is a partial GABA<sub>A</sub> receptor positive allosteric modulator with relatively high efficacy at the α1 subunit.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>ONO-8590580</b> <span style="float: right;">Cat. No.: HY-112788</span></p> <p>ONO-8590580 is a GABA<sub>A</sub> α5 negative allosteric modulator.</p> <p><b>Purity:</b> 99.13%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p><b>Org20599</b> <span style="float: right;">Cat. No.: HY-103498</span></p> <p>Org20599 is a positive allosteric modulator and at higher concentrations direct agonist of GABA<sub>A</sub> receptor with an EC<sub>50</sub> of 1.1 μM.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Oxiracetam</b> (ISF2522) <span style="float: right;">Cat. No.: HY-B1715</span></p> <p>Oxiracetam is a cyclic derivative of γ-aminobutyric acid (GABA) which has been commonly used as nootropic drug to treat cognitive impairments.</p> <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p> 	<p><b>p-Hydroxybenzaldehyde</b> <span style="float: right;">Cat. No.: HY-Y0313</span></p> <p>p-Hydroxybenzaldehyde is a one of the major components in Dendrocalamus asper bamboo shoots, with antagonistic effect on GABA<sub>A</sub> receptor of the α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub>S subtype at high concentrations.</p> <p><b>Purity:</b> 97.16%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 100 mg</p> 
<p><b>p-Hydroxybenzaldehyde-13C</b> <span style="float: right;">Cat. No.: HY-Y0313S1</span></p> <p>p-Hydroxybenzaldehyde-13C is the 13C-labeled p-Hydroxybenzaldehyde. p-Hydroxybenzaldehyde is a one of the major components in Dendrocalamus asper bamboo shoots, with antagonistic effect on GABA<sub>A</sub> receptor of the α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub>S subtype at high concentrations.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>p-Hydroxybenzaldehyde-d4</b> <span style="float: right;">Cat. No.: HY-Y0313S</span></p> <p>p-Hydroxybenzaldehyde-d4 is the deuterium labeled p-Hydroxybenzaldehyde. p-Hydroxybenzaldehyde is a one of the major components in Dendrocalamus asper bamboo shoots, with antagonistic effect on GABA<sub>A</sub> receptor of the α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub>S subtype at high concentrations.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 25 mg, 100 mg, 250 mg</p> 























<p><b>PF-06372865</b></p> <p style="text-align: right;">Cat. No.: HY-120874</p> <p>PF-06372865 is an orally active, <math>\alpha 2/\alpha 3/\alpha 5</math> subtype-selective <math>GABA_A</math> positive allosteric modulator (PAM).</p>  <p><b>Purity:</b> 98.11%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Phaclofen</b></p> <p style="text-align: right;">Cat. No.: HY-100798</p> <p>Phaclofen is a selective <math>GABA_B</math> receptor antagonist. Phaclofen is a peripheral and central baclofen antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Picamilon</b> (Nicotinoyl-GABA; Nicotinoyl-<math>\gamma</math>-aminobutyric acid)</p> <p style="text-align: right;">Cat. No.: HY-107482</p> <p>Picamilon is a derivative of <math>\gamma</math>-aminobutyric acid that has nootropic effect.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Picrotoxinin</b></p> <p style="text-align: right;">Cat. No.: HY-B1494</p> <p>Picrotoxinin, a potent convulsant, is a chloride channel blocker. Picrotoxinin is a noncompetitive <math>GABA_A</math> receptor antagonist, which negatively modulates the action of GABA on <math>GABA_A</math> receptors.</p>  <p><b>Purity:</b> 97.03%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mg</p>
<p><b>Pipequaline</b> (PK-8165)</p> <p style="text-align: right;">Cat. No.: HY-100140</p> <p>Pipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity.</p>  <p><b>Purity:</b> 99.77%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>Pipequaline hydrochloride</b> (PK-8165 hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-100140A</p> <p>Pipequaline hydrochloride (PK-8165 hydrochloride) is a partial benzodiazepine receptor agonist with anxiolytic activity.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Piperazine citrate</b> (1,4-Diazacyclohexane citrate)</p> <p style="text-align: right;">Cat. No.: HY-17599</p> <p>Piperazine (1,4-Diazacyclohexane) citrate is a gamma-aminobutyric acid (GABA) agonist. Piperazine citrate is a vital building block and is an essential core in numerous marketed drugs with diverse pharmacological activities.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 500 mg</p>	<p><b>Pivagabine</b> (CXB-722)</p> <p style="text-align: right;">Cat. No.: HY-108295</p> <p>Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats.</p>  <p><b>Purity:</b> <math>\geq</math>99.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg</p>
<p><b>Pregabalin arenacarbil</b></p> <p style="text-align: right;">Cat. No.: HY-109156</p> <p>Pregabalin arenacarbil is a prodrug of Pregabalin. Pregabalin is an analog of gamma-aminobutyric acid (GABA) for the research of post herpetic neuralgia, peripheral diabetic neuropathy, fibromyalgia and epilepsy.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Progabide</b> (SL 76002)</p> <p style="text-align: right;">Cat. No.: HY-A0173</p> <p>Progabide is a gamma-aminobutyric acid receptor (GABA) agonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Propofol</b> (2,6-Diisopropylphenol)</p> <p>Propofol potently and directly activates <math>GABA_A</math> receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic.</p> <p><b>Purity:</b> 99.52% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 100 mg</p>	<p><b>Propofol-d17</b></p> <p>Propofol-d17 (2,6-Diisopropylphenol-d17) is the deuterium labeled Propofol. Propofol potently and directly activates <math>GABA_A</math> receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 2.5 mg, 1 mg, 5 mg, 10 mg</p>
<p><b>Propofol-d18</b></p> <p>Propofol-d18 is the deuterium labeled Propofol. Propofol potently and directly activates <math>GABA_A</math> receptor and inhibits glutamate receptor mediated excitatory synaptic transmission.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>rac-BHFF</b></p> <p>rac-BHFF is a potent and orally active allosteric enhancer of <math>GABA_B</math> receptor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Radequinil</b> (AC-3933)</p> <p>Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to <math>GABA(-)</math> and <math>GABA(+)</math> ligand with <math>K_S</math> of 5.15 and 6.11 nM, respectively.</p> <p><b>Purity:</b> 99.67% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Rilmazafone</b></p> <p>Rilmazafone is a benzodiazepine <math>\omega</math> ligand and an orally active sleep inducer.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Rilmazafone hydrochloride</b> (450191S)</p> <p>Rilmazafone hydrochloride (450191S) is a benzodiazepine <math>\omega</math> ligand.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Riluzole</b> (PK 26124)</p> <p>Riluzole is an anticonvulsant drug and belongs to the family of use-dependent <math>Na^+</math> channel blocker which can also inhibit <math>GABA</math> uptake with an <math>IC_{50}</math> of 43 <math>\mu M</math>.</p> <p><b>Purity:</b> 99.80% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g</p>
<p><b>Riluzole hydrochloride</b> (PK 26124 hydrochloride)</p> <p>Riluzole hydrochloride is an anticonvulsant drug and belongs to the family of use-dependent <math>Na^+</math> channel blocker which can also inhibit <math>GABA</math> uptake with an <math>IC_{50}</math> of 43 <math>\mu M</math>.</p> <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 50 mg, 100 mg, 500 mg</p>	<p><b>Ro 41-3290</b></p> <p>Ro 41-3290 is the desethylated derivative of Ro 41-3696, which is a nonbenzodiazepine partial agonist at the benzodiazepine receptor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>RO 4938581</b></p> <p>Cat. No.: HY-107489</p>	<p><b>Ro15-4513</b></p> <p>Cat. No.: HY-103476</p>
<p>RO 4938581 is a potent and selective <b>GABA<sub>A</sub> α5</b> inverse agonist, with a <math>K_i</math> of 4.6 nM for <b>GABA<sub>A</sub> α5β3γ2a</b>, and shows a lower affinity at α1β3γ2a, α2β3γ2a, α3β3γ2a (<math>K_i</math>, 174, 185, 80 nM, respectively); RO 4938581 is used in the research of cognitive dysfunction.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Ro15-4513, imidazobenzodiazepinone derivative, is a partial inverse agonist of <b>benzodiazepine receptor (BZR)</b>. Ro15-4513 is a potent <b>ethanol antagonist</b>. Ro15-4513 has anti-anxiety effect.</p> <p><b>Purity:</b> ≥98.0%</p> <p><b>Clinical Data:</b> Phase 1</p> <p><b>Size:</b> 10 mM × 1 mL, 1 mg, 5 mg, 10 mg</p>
<p><b>Ru-32514</b></p> <p>Cat. No.: HY-19065</p>	<p><b>RWJ-51204</b></p> <p>Cat. No.: HY-19308</p>
<p>Ru-32514 is an agonist of benzodiazepine receptor.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>RWJ-51204 is a partial agonist of <b>GABA(A) receptor</b>, with <math>K_i</math> of 0.2-2 nM to the benzodiazepine site on GABA(A) receptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>S-8510 phosphate</b> (SB-737552 phosphate)</p> <p>Cat. No.: HY-103225</p>	<p><b>Saclofen</b></p> <p>Cat. No.: HY-100813</p>
<p>S-8510 (phosphate) is an inverse <b>Benzodiazepine (BDZ) receptor</b> agonist, with <math>K_s</math> of 34.6 nM, 36.2 nM for -GABA and +GABA respectively.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Saclofen is a competitive antagonist of the <b>GABA<sub>B</sub> receptor</b> with an <math>IC_{50}</math> of 7.8 μM. Saclofen can be used to determine the functional roles for the <b>GABA<sub>B</sub> receptor</b> as a mediator of slow inhibitory postsynaptic potentials in the brain.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Sarmazenil</b> (Ro 15-3505)</p> <p>Cat. No.: HY-100248</p>	<p><b>SCH 50911</b></p> <p>Cat. No.: HY-12783A</p>
<p>Sarmazenil is a <b>benzodiazepine receptor</b> antagonist.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>SCH 50911, (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid, a selective, orally-active and competitive <b>γ-Aminobutyric acid B GABA(B) receptor</b> antagonist, binds to GABA(B) receptor with <math>IC_{50}</math> of 1.1 μM.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>SCH 50911 hydrochloride</b></p> <p>Cat. No.: HY-12783</p>	<p><b>SJM-3</b></p> <p>Cat. No.: HY-131941</p>
<p>SCH 50911 hydrochloride, (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid, a selective, orally-active and competitive <b>γ-Aminobutyric acid B GABA(B) receptor</b> antagonist, binds to GABA(B) receptor with <math>IC_{50}</math> of 1.1 μM.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>SJM-3 is a positive allosteric modulator of different isoforms of the <b>GABAA</b> receptor. SJM-3 binds at the high-affinity benzodiazepine binding site at the α+/γ- subunit interface.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg</p>

<p><b>SKF89976A hydrochloride</b> (d,l-SKF89976A hydrochloride)</p> <p>SKF89976A hydrochloride is a selective <b>GABA transporter (GAT-1)</b> inhibitor with <math>IC_{50}</math>s of 0.28 <math>\mu</math>M, 137.34 <math>\mu</math>M and 202.8 <math>\mu</math>M for GAT-1, GAT-2 and GAT-3 in CHO cells, respectively.</p> <p><b>Purity:</b> 99.70% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg</p>	<p><b>Songorine</b></p> <p>Songorine is a diterpenoid alkaloid isolated from the genus <i>Aconitum</i>. Songorine is a <b>GABAA receptor</b> antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC).</p> <p><b>Purity:</b> 98.48% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 20 mg</p>
<p><b>SSD114 hydrochloride</b></p> <p>SSD114 hydrochloride is a novel <b>GABA<sub>B</sub> receptor</b> positive allosteric modulator.</p> <p><b>Purity:</b> 99.07% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>SX-3228</b></p> <p>SX-3228 is a selective <b>benzodiazepine1 (BZ1)</b> receptor agonist with an <math>IC_{50}</math> of 17 nM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>TACA</b> (trans-4-Aminocrotonic acid)</p> <p>TACA (trans-4-Aminocrotonic acid) is a potent agonist of <b>GABA<sub>A</sub></b> and <b>GABA<sub>C</sub></b> receptors (<math>K_D</math>= 0.6 <math>\mu</math>M). TACA also is GABA uptake inhibitor and substrate for GABA-T. TACA produces late biphasic responses in the MPG neurons.</p> <p><b>Purity:</b> 99.33% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>TB-21007</b></p> <p>TB-21007 is an inverse agonist of <math>\alpha_5\beta_3\gamma_2</math> subunit-containing <b>GABA<sub>A</sub> receptor</b> with a <math>K_i</math> of 1.6 nM. TB-21007 enhanced spatial memory in rats.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Temgicoluril</b> (Tetramethylglycoluril; Mebicar)</p> <p>Tetramethylglycerol (Tetramethylglycoluril) is a small molecule that acts on <b>GABA Receptor</b>, with anti-anxiety activity.</p> <p><b>Purity:</b> 98.06% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 50 mg, 100 mg</p>	<p><b>Tetrahydrodeoxycorticosterone</b> (Tetrahydro-11-deoxycorticosterone)</p> <p>Tetrahydrodeoxycorticosterone, a neurosteroid, is a potent positive allosteric modulator (PAM) of <b>GABA<sub>A</sub> receptor</b>. Tetrahydrodeoxycorticosterone has potent neuroinhibitory properties.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Tetrahydrodeoxycorticosterone-d3</b> (Tetrahydro-11-deoxycorticosterone-d3)</p> <p>Tetrahydrodeoxycorticosterone-d3 is the deuterium labeled Tetrahydrodeoxycorticosterone. Tetrahydrodeoxycorticosterone, a neurosteroid, is a potent positive allosteric modulator (PAM) of <b>GABA<sub>A</sub> receptor</b>. Tetrahydrodeoxycorticosterone has potent neuroinhibitory properties.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Thiocolchicoside</b></p> <p>Thiocolchicoside is a competitive <b><math>\gamma</math>-aminobutyric acid type A (GABA<sub>A</sub>) receptor</b> antagonist and <b>glycine receptor</b> agonist in the central nervous system. Thiocolchicoside is a semisynthetic sulfur derivative of colchicoside.</p> <p><b>Purity:</b> 99.23% <b>Clinical Data:</b> Phase 4 <b>Size:</b> 5 mg, 10 mg, 20 mg</p>

<p><b>THIP</b> (Gaboxadol)</p>	<p><b>Cat. No.:</b> HY-10232</p>	<p>THIP (Gaboxadol) is a selective <math>\delta</math>-aminobutyric acid type A receptor (<math>\delta</math>-GABAAR) agonist, functionally selective GABAAR ligand, exhibits agonism at <math>\alpha 4\beta 1\delta</math>, <math>\alpha 4\beta 3\delta</math> and weak antagonism at <math>\alpha \beta \gamma</math> and <math>\alpha 4\beta 2\delta</math> GABAARs.</p> <p><b>Purity:</b> 99.75% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 10 mM <math>\times</math> 1 mL, 25 mg</p>	<p><b>Cat. No.:</b> HY-B0696</p> <p>Tiagabine (NO050328) is a potent and selective <b>GABA reuptake</b> inhibitor, used as an anticonvulsant agent, with <math>IC_{50}</math>s of 67, 446 and 182 nM for [<math>^3H</math>]GABA uptake in Synaptosomes, Neurons and Glia, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 25 mg</p>
			
<p><b>Tiagabine hydrochloride</b> (NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride)</p> <p><b>Cat. No.:</b> HY-B0696A</p>	<p><b>Tiagabine hydrochloride hydrate</b> (NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; ...)</p> <p><b>Cat. No.:</b> HY-B0696B</p>		
<p>Tiagabine hydrochloride is a potent and selective <b>GABA reuptake</b> inhibitor, used as an anticonvulsant agent, with <math>IC_{50}</math>s of 67, 446 and 182 nM for [<math>^3H</math>]GABA uptake in Synaptosomes, Neurons and Glia, respectively.</p> <p><b>Purity:</b> 99.67% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Tiagabine hydrochloride hydrate is a potent and selective <b>GABA uptake</b> inhibitor, used as an anticonvulsant agent, with <math>IC_{50}</math>s of 67, 446 and 182 nM for [<math>^3H</math>]GABA uptake in Synaptosomes, Neurons and Glia, respectively.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 5 mg</p>		
			
<p><b>Tigolaner</b></p> <p><b>Cat. No.:</b> HY-109077</p>	<p><b>Tigolaner-d4</b></p> <p><b>Cat. No.:</b> HY-109077S</p>		
<p>Tigolaner is a <b>GABA</b> antagonist that regulates chloride channel. Tigolaner is an antiparasitic agent.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Tigolaner-d4 is deuterium labeled Tigolaner. Tigolaner is a GABA antagonist that regulates chloride channel. Tigolaner is an antiparasitic agent.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>		
			
<p><b>Topiramate</b> (McN 4853; RWJ 17021)</p> <p><b>Cat. No.:</b> HY-B0122</p>	<p><b>Topiramate D12</b> (McN 4853 D12; RWJ 17021 D12)</p> <p><b>Cat. No.:</b> HY-110234</p>		
<p>Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a <b>Glur5 receptor</b> antagonist.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg, 500 mg</p>	<p>Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a <b>Glur5 receptor</b> antagonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg</p>		
			
<p><b>TP003</b></p> <p><b>Cat. No.:</b> HY-103512</p>	<p><b>TPA 023</b></p> <p><b>Cat. No.:</b> HY-101640</p>		
<p>TP003 is a non-selective benzodiazepine site agonist with <math>EC_{50}</math>s of 20.3, 10.6, 3.24, 5.64 nM for <math>\alpha 1\beta 2\gamma 2</math>, <math>\alpha 2\beta 3\gamma 2</math>, <math>\alpha 3\beta 3\gamma 2</math>, <math>\alpha 5\beta 2\gamma 2</math>, respectively. TP003 induces anxiolysis via <math>\alpha 2GABA_A</math> receptors.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>TPA 023 is a <b>GABAA <math>\alpha 2/\alpha 3</math></b> subtype-selective agonist, with <math>K_i</math> of 0.19-0.41 nM.</p> <p><b>Purity:</b> 99.71% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 1 mg, 5 mg, 10 mg</p>		
			

<p><b>TPA-023B</b></p> <p>Cat. No.: HY-19505</p> <p>TPA-023B is a high-affinity and orally active <b>GABA<sub>A</sub></b> receptor <math>\alpha 2/\alpha 3</math> subtype (<math>K_s</math> of 0.73 nM/2 nM) partial agonist and a <math>\alpha 1</math> subtype (<math>K_i</math> of 1.8 nM) antagonist. TPA-023B has non-sedating anxiolytic-like properties.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>TPMPA</b></p> <p>Cat. No.: HY-101359</p> <p>TPMPA, a hybrid of isoguvacine and 3-APMPA, is the first selective antagonist for a <b>GABA<sub>C</sub></b> receptor (<math>K_B = 2.1 \mu\text{M}</math>), but not to interact with <b>GABA<sub>A</sub></b> (<math>K_B = 320 \mu\text{M}</math>) or <b>GABA<sub>B</sub></b> receptors (<math>EC_{50} = 500 \mu\text{M}</math>).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Tracazolate hydrochloride</b> (ICI 136753 hydrochloride)</p> <p>Cat. No.: HY-B1803A</p> <p>Tracazolate (ICI 136753) hydrochloride is a potent <b>GABA<sub>A</sub></b> receptor modulator. Tracazolate hydrochloride has selectivity for <math>\beta 3</math> and potentiates <math>\alpha 1\beta 1\gamma 2s</math> (<math>EC_{50}=13.2 \mu\text{M}</math>), <math>\alpha 1\beta 3\gamma 2</math> (<math>EC_{50}=1.5 \mu\text{M}</math>).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>U-101017</b> (PNU 101017)</p> <p>Cat. No.: HY-19250</p> <p>U-101017 is a partial agonist of <b>benzodiazepine receptor</b> and <b>GABA<sub>A</sub> receptor</b>, with anxiolytic effects.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>U93631</b></p> <p>Cat. No.: HY-100686</p> <p>U93631 is a <b>GABA<sub>A</sub></b> receptor ligand of novel chemical structure with <math>IC_{50}</math> of 100 nM, and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell <math>Cl^-</math> currents in recombinant <b>GABA<sub>A</sub></b> receptors.</p> <p><b>Purity:</b> 99.85%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p><b>Uldazepam</b> (U31920)</p> <p>Cat. No.: HY-100264</p> <p>Uldazepam is a benzodiazepine derivative and has the potential for anxiety syndrome treatment.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Valerenic acid</b> (-)-Valerenic Acid)</p> <p>Cat. No.: HY-103524</p> <p>Valerenic acid ((-)-Valerenic Acid), a sesquiterpenoid, is an orally active positive allosteric modulator of <b>GABA<sub>A</sub></b> receptors. Valerenic acid is also a partial agonist of the <b>5-HT<sub>2a</sub></b> receptor.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Valnoctamide</b> (Valmethamide)</p> <p>Cat. No.: HY-121877</p> <p>Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on <b>GABA<sub>A</sub></b> receptors.</p> <p><b>Purity:</b> <math>\geq 99.0\%</math>  <b>Clinical Data:</b> Phase 3  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p> 
<p><b>Valnoctamide-d5</b></p> <p>Cat. No.: HY-121877S</p> <p>Valnoctamide-d5 (Valmethamide-d5) is the deuterium labeled Valnoctamide. Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on <b>GABA<sub>A</sub></b> receptors.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b>  <b>Size:</b> 1 mg, 10 mg</p> 	<p><b>Vigabatrin</b> (<math>\gamma</math>-Vinyl-GABA)</p> <p>Cat. No.: HY-15399</p> <p>Vigabatrin (<math>\gamma</math>-Vinyl-GABA), an inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible <b>GABA transaminase inhibitor</b>.</p> <p><b>Purity:</b> <math>\geq 98.0\%</math>  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p> 

<p><b>Vigabatrin hydrochloride</b> (<math>\gamma</math>-Vinyl-GABA hydrochloride)</p> <p>Vigabatrin hydrochloride (<math>\gamma</math>-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible <b>GABA transaminase</b> inhibitor.</p> <p><b>Purity:</b> <math>\geq 99.0\%</math> <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>	<p><b>Vigabatrin-13C,d2 hydrochloride</b> (<math>\gamma</math>-Vinyl-GABA-13C,d2 hydrochloride)</p> <p>Vigabatrin-13C,d2 (hydrochloride) is the 13C- and deuterium labeled. Vigabatrin hydrochloride (<math>\gamma</math>-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Zuranolone</b></p> <p>Zuranolone is an orally active and potent neuroactive steroid positive allosteric modulator of <b>GABA<sub>A</sub> receptor</b>, with EC<sub>50</sub>s of 296 and 163 nM for <math>\alpha_1\beta_2\gamma_2</math> and <math>\alpha_1\beta_3\delta</math> <b>GABA<sub>A</sub> receptors</b>, respectively.</p> <p><b>Purity:</b> 99.96% <b>Clinical Data:</b> Phase 3 <b>Size:</b> 10 mM <math>\times</math> 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b><math>\alpha</math>-Thujone</b></p> <p><math>\alpha</math>-Thujone is a monoterpene isolated from Thuja occidentalis essential oil with potent anti-tumor activities. <math>\alpha</math>-Thujone is a reversible modulator of the <b>GABA type A receptor</b> and the IC<sub>50</sub> for <math>\alpha</math>-Thujone is 21 <math>\mu</math>M in suppressing the <b>GABA</b>-induced currents.</p> <p><b>Purity:</b> <math>\geq 95.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 50 mg, 100 mg</p>
<p><b><math>\gamma</math>-Acetylenic GABA</b> (4-Aminohex-5-ynoic acid)</p> <p><math>\gamma</math>-Acetylenic GABA (4-Aminohex-5-ynoic acid) is an irreversible inhibitor of <b>GABA-transaminase</b>. <math>\gamma</math>-Acetylenic GABA can increase the concentration of GABA in rat brain.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b><math>\gamma</math>-Aminobutyric acid</b> (4-Aminobutyric acid)</p> <p><math>\gamma</math>-Aminobutyric acid (4-Aminobutyric acid) is a major inhibitory neurotransmitter in the adult mammalian brain, binding to the ionotropic GABA receptors (<b>GABA<sub>A</sub> receptors</b>) and metabotropic receptors (<b>GABA<sub>B</sub> receptors</b>).</p> <p><b>Purity:</b> <math>\geq 98.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>
<p><b><math>\gamma</math>-Aminobutyric acid-13C4</b> (4-Aminobutyric acid-13C4)</p> <p><math>\gamma</math>-Aminobutyric acid-13C4 (4-Aminobutyric acid-13C4) is the 13C-labeled <math>\gamma</math>-Aminobutyric acid.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b><math>\gamma</math>-Aminobutyric acid-4,4-d2</b> (4-Aminobutyric acid-4,4-d2)</p> <p><math>\gamma</math>-Aminobutyric acid-4,4-d2 (4-Aminobutyric acid-4,4-d2) is the deuterium labeled <math>\gamma</math>-Aminobutyric acid.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b><math>\gamma</math>-Aminobutyric acid-d2</b> (4-Aminobutyric acid-d2)</p> <p><math>\gamma</math>-Aminobutyric acid-d2 (4-Aminobutyric acid-d2) is the deuterium labeled <math>\gamma</math>-Aminobutyric acid.</p> <p><b>Purity:</b> <math>&gt; 98\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b><math>\gamma</math>-Aminobutyric acid-d6</b> (4-Aminobutyric acid-d6)</p> <p><math>\gamma</math>-Aminobutyric acid-d6 (4-Aminobutyric acid-d6) is the deuterium labeled <math>\gamma</math>-Aminobutyric acid.</p> <p><b>Purity:</b> <math>\geq 99.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg</p>